BIOCAD Keeps on Supplying Its Medicine for Blood Cancer Treatment in Vietnam
30 March 2017 - 9:10AM
Business Wire
In March BIOCAD biotechnology company was granted access to
supply highly demanded medicine - rituximab biosimilar to Vietnam
for a second time. It means that BIOCAD partners will continue to
supply local hospitals with the Russian product and patients will
get access to affordable and effective treatment in Vietnam.
BIOCAD is going to receive permanent registration certificate
for the medicine in the end of the 3rd - beginning of the
4thquarter 2017. It will allow the company to export the product
from Russia without any limitations.
International expansion is one of BIOCAD’s strategic goals and
entering a new market is always an achievement. Vietnam is among
the company’s priority markets, because it is one of the
fastest-growing economies in Southeast Asia.
Today rituximab biosimilar developed and produced by BIOCAD has
already entered international markets including Southeast Asia,
Middle East, and CIS countries. By the end of 2017 the medicine
should appear in the markets of India and Sri-Lanka.
About company
BIOCAD is global leading innovative biotechnology company in
Russia. Its leading excellence comes from the world-class R&D
centers, modern biotechnological manufacturing facilities, as well
as preclinical and clinical research infrastructure that
corresponds to the international standards.
BIOCAD is a full-cycle drug development and manufacturing
company, ensuring high-quality pharmaceutical development in all
stages—from new genetic engineering to large-scale commercial
production and further marketing support. The company provides
original and generic drug products to treat complex health
conditions such as cancer, HIV, multiple sclerosis, Hepatitis C
infections, and other disorders.
The company employs about 1200 workers, including more than 450
researchers. In 2016, the revenue of the company exceeded 14
billion rubles, and the total value of its international long-term
contracts reached 850 million USD. BIOCAD has created subsidiaries
and partnerships in the USA, Brazil, China, India, and other
countries.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170330005476/en/
BIOCADIrina KenyukhovaPhone +7 (812) 3804933, ext.
632E-mail kenyukhova@biocad.ru